tanomastat   Click here for help

GtoPdb Ligand ID: 6468

Synonyms: BAY 12-9566 | BAY-12-9566 | BAY-129566
Compound class: Synthetic organic
Comment: This compound failed testing in Phase 3 clinical trials.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 79.67
Molecular weight 410.07
XLogP 6.19
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)C(CC(=O)c1ccc(cc1)c1ccc(cc1)Cl)CSc1ccccc1
Isomeric SMILES OC(=O)[C@H](CC(=O)c1ccc(cc1)c1ccc(cc1)Cl)CSc1ccccc1
InChI InChI=1S/C23H19ClO3S/c24-20-12-10-17(11-13-20)16-6-8-18(9-7-16)22(25)14-19(23(26)27)15-28-21-4-2-1-3-5-21/h1-13,19H,14-15H2,(H,26,27)/t19-/m1/s1
InChI Key JXAGDPXECXQWBC-LJQANCHMSA-N
References
1. Fisher JF, Mobashery S. (2006)
Recent advances in MMP inhibitor design.
Cancer Metastasis Rev, 25 (1): 115-36. [PMID:16680577]
2. Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L. (2006)
A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.
Gynecol Oncol, 102 (2): 300-8. [PMID:16442153]